Skip to main content
307 search results for:

Ankylosing spondylitis 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 06-08-2022 | Ankylosing spondylitis | Adis Journal Club | Article
    Rheumatology and Therapy

    Development and Validation of a Machine Learning-Based Nomogram for Prediction of Ankylosing Spondylitis

    Authors: Jichong Zhu, Qing Lu, Tuo Liang, JieJiang, Hao Li, Chenxin Zhou, Shaofeng Wu, Tianyou Chen, Jiarui Chen, Guobing Deng, Yuanlin Yao, Shian Liao, Chaojie Yu, Shengsheng Huang, Xuhua Sun, Liyi Chen, Wenkang Chen, Zhen Ye, Hao Guo, Wuhua Chen, Wenyong Jiang, Binguang Fan, Xiang Tao, Xinli Zhan & Chong Liu Abstract Introduction Ankylosing spondylitis (AS) is a chronic progressive inflammatory disease of the spine and its affiliated tissues.

  2. 19-07-2022 | Bimekizumab | News | Article

    Bimekizumab demonstrates sustained benefits in PsA, ankylosing spondylitis

    Follow-up results from the BE ACTIVE and BE AGILE phase 2b trials show that the efficacy and safety profiles of bimekizumab are maintained for up to 3 years in patients with psoriatic arthritis or ankylosing spondylitis.

  3. 09-08-2022 | Axial spondyloarthritis | News | Article

    Substantial lifetime risk for axSpA among relatives of patients with ankylosing spondylitis

    A 35-year follow-up study has identified a 27.1% lifetime recurrence rate of axial spondyloarthritis among first-degree relatives of patients with human leukocyte antigen HLA-B27-positive ankylosing spondylitis.

  4. 12-08-2022 | Ankylosing spondylitis | Adis Journal Club | Article
    Advances in Therapy

    Levels of Peripheral Th17 Cells and Th17-Related Cytokines in Patients with Ankylosing Spondylitis: A Meta-analysis

    DOI [Teaser] Key Summary Points The levels of T helper 17 (Th17) cells and serum interleukin (IL)-17, IL-21 and IL-23 were higher in patients with ankylosing spondylitis (AS) than in healthy controls.

  5. 23-03-2022 | Axial spondyloarthritis | News | Article

    Acute anterior uveitis may point to axSpA risk in relatives of people with ankylosing spondylitis

    Researchers have identified factors that may signal increased axial spondyloarthritis risk among family members of patients with ankylosing spondylitis, including the presence of acute anterior uveitis.

  6. 29-03-2022 | Ankylosing spondylitis | Adis Journal Club | Article
    BioDrugs

    Clinical Features and Drug Retention of TNF Inhibitors in Older Patients with Ankylosing Spondylitis: Results from the KOBIO Registry

    Fewer patients were male, the incidence of hypertension and diabetes was higher (all  p  < 0.001), and the proportion of peripheral arthritis (35.6 vs. 27.1%), Ankylosing Spondylitis Disease Activity Score‒erythrocyte sedimentation rate (4.0 ± 1.1 vs. 3.6 ± 1.0), and Bath Ankylosing Spondylitis Functional Index (4.2 ± 2.6 vs. 3.3 ± 2.5) were all higher in older patients.

  7. 18-12-2020 | Upadacitinib | News | Article
    approvalsWatch

    EMA gives nod to upadacitinib for psoriatic arthritis, ankylosing spondylitis

    medwireNews : The EMA’s Committee for Medicinal Products for Human Use has recommended that the indication for upadacitinib should be expanded to include psoriatic arthritis (PsA) and ankylosing spondylitis (AS).

  8. 20-12-2021 | Ankylosing spondylitis | News | Article
    approvalsWatch

    Tofacitinib given restricted FDA approval for ankylosing spondylitis

    medwireNews : The Janus kinase (JAK) inhibitor tofacitinib may be used for the treatment of active ankylosing spondylitis (AS) in adults with an inadequate response or intolerance to tumor necrosis factor (TNF) inhibitors, says the US FDA.

  9. 19-10-2021 | Ankylosing spondylitis | News | Article
    approvalsWatch

    Tofacitinib receives EMA support for ankylosing spondylitis

    medwireNews : Tofacitinib could soon be available in Europe for people with ankylosing spondylitis following a recommendation from the EMA  to adopt a new indication for the drug.

  10. 02-02-2022 | Ankylosing spondylitis | Adis Journal Club | Article
    Advances in Therapy

    Disease Activity-Guided Stepwise Tapering but Not Discontinuation of Biologics Is a Feasible Therapeutic Strategy for Patients with Ankylosing Spondylitis: Real-World Evidence

    Compared with the baseline parameters, after 3-month and 12-month treatments disease activities were improved significantly, including Patient Global Assessment (PTGA), overall back pain, nocturnal pain, fatigue, Ankylosing Spondylitis Disease Activity Score–C-Reactive Protein (ASDAS-CRP), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and Bath Ankylosing Spondylitis Functional Index (BASFI). (2) Only 59.3% used ETN biosimilars with full dose (3.5 days’ interval) in the first 3 months.

  11. 16-08-2021 | Ankylosing spondylitis | News | Article
    News in brief

    Filgotinib may improve MRI structural lesions in ankylosing spondylitis

    A post-hoc analysis of data from the TORTUGA trial shows that treatment with filgotinib is associated with beneficial changes in MRI structural lesions in people with ankylosing spondylitis.

  12. 22-02-2021 | Ankylosing spondylitis | News | Article

    No benefit of apremilast for patients with ankylosing spondylitis

    The phase 3 POSTURE trial has demonstrated no clinical benefit of apremilast for patients with active ankylosing spondylitis and no prior exposure to biologic agents.

  13. 15-03-2021 | Secukinumab | News | Article

    Secukinumab alternatives suggested for ankylosing spondylitis patients with pre-existing IBD

    Researchers report that secukinumab is associated with an increased risk for gastrointestinal-related adverse events in patients with ankylosing spondylitis and pre-existing inflammatory bowel disease and say that prescribing alternatives should be considered.

  14. play
    09-11-2020 | ACR 2020 | Conference coverage | Video

    Tofacitinib shows promise for ankylosing spondylitis

    Lead investigator Atul Deodhar outlines the results of a phase 3 trial investigating tofacitinib as treatment option for ankylosing spondylitis, and discusses how JAK inhibitors might impact the spondyloarthritis treatment landscape.

  15. 11-11-2020 | Ankylosing spondylitis | Teaser
    Expert interview

    Tofacitinib shows promise for ankylosing spondylitis

    Lead investigator Atul Deodhar outlines the results of a phase 3 trial investigating tofacitinib as treatment option for ankylosing spondylitis, and discusses how JAK inhibitors might impact the spondyloarthritis treatment landscape (5:36).

  16. 10-11-2020 | ACR 2020 | Conference coverage | Article

    Phase 3 trial demonstrates benefits of tofacitinib in ankylosing spondylitis

    The JAK inhibitor tofacitinib is a promising treatment option for people with ankylosing spondylitis, suggest phase 3 trial findings presented at the ACR Convergence 2020 virtual meeting.

  17. 29-07-2020 | Ankylosing spondylitis | News | Article

    TNF inhibitors may slow radiographic progression in ankylosing spondylitis

    Patients with ankylosing spondylitis taking TNF inhibitors experience slower rates of radiographic progression than those not taking TNF inhibitors, suggest long-term, real-world findings.

  18. 12-11-2019 | Ankylosing spondylitis | ACR/ARP 2019 | Article

    Upadacitinib demonstrates potential for ankylosing spondylitis

    Findings from the phase II/III SELECT-AXIS 1 trial suggest that treatment with upadacitinib may improve disease activity, function, and axial inflammation among biologic-naïve patients with ankylosing spondylitis and an inadequate response or intolerance to NSAIDs.

  19. 03-07-2020 | Infliximab | News | Article

    EMA approves subcutaneous infliximab for PsA, ankylosing spondylitis

    medwireNews : The EMA’s Committee for Medicinal Products for Human Use has expanded the indication of subcutaneous infliximab to include psoriatic arthritis (PsA) and ankylosing spondylitis (AS).

  20. 12-11-2019 | Ankylosing spondylitis | ACR/ARP 2019 | Article

    Bimekizumab benefits for ankylosing spondylitis extend beyond 12 weeks

    Bimekizumab shows sustained benefit in the treatment of patients with ankylosing spondylitis, 48-week data show.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.